BRAF and thyroid cancer: In addition, 25–50% of thyroid cancers are BRAF mutated and constitutive activation of BRAF signaling leads to aggressive malignancies, lacking typical traits of thyroid differentiation [2, 12] and, thus, poorly responsive to radioiodine therapy [13].